profit from every $100 of sales.
$0$100
Ligand Pharmaceuticals
$316.27-0.18% today
+53.8% in 1 year
1-year low $181.651-year high $322.75
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $50.83 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Ligand Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $196 million in 2022 to $268 million in 2025, with $124 million of profit last year.
SalesProfit
Ligand Pharmaceuticals handed back 39% of the cash it generated last year.
Buybacks $15M
Free cash flow 2025$38M
Bought back its own shares$15M
Paid as dividends–
Cash vs. debt$175M vs. $451M
Ligand Pharmaceuticals vs. similar companies
Ligand Pharmaceuticals grows the slowest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ligand Pharmaceuticals | 50.8× · Expensive | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Ligand Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 164 | 242 | 196 | 131 | 167 | 268 | |
| – | – | 143 | 121 | 156 | 254 | |
| – | – | 3 | 10 | 23 | 47 | |
| 54 | 143 | 89 | 101 | 41 | 197 | |
| -3 | 57 | -33 | 52 | -4 | 124 | |
| -0.18 | 3.31 | -1.98 | 2.94 | -0.22 | 6.13 | |
| – | – | 73.1% | 92.0% | 93.4% | 94.6% | |
| – | – | 1.5% | 7.5% | 13.8% | 17.6% | |
| -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1,362 | 1,298 | 763 | 787 | 942 | 1,561 |
| Cash | 48 | 20 | 45 | 23 | 72 | 175 |
| Total debt | – | – | 88 | 6 | 7 | 451 |
| Total liabilities | 653 | 476 | 165 | 86 | 111 | 543 |
| 710 | 821 | 597 | 701 | 830 | 1,017 | |
| 17 | 17 | 17 | 18 | 18 | 20 | |
| 3.2% | 8.8% | 4.4% | 7.2% | 0.5% | 8.8% | |
| -0.4% | 7.0% | -5.6% | 7.4% | -0.5% | 12.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 55 | 79 | 138 | 50 | 97 | 49 | |
| – | – | 18 | 54 | 20 | 11 | |
| – | – | 120 | -4 | 77 | 38 | |
| Dividends paid | – | – | – | – | – | – |
| 78 | 0 | 0 | 0 | 0 | 15 | |
| 31 | 39 | 60 | 26 | 41 | 47 |
Valuation
- 50.8×
- 35.6×
- –
- 4.7×
- 23.6×
- 166.3×
- 33.4×
- 0.6%
- 2.0%
- 0.0%
Profitability
- 94.6%
- 17.6%
- 46.4%
- 92.5%
- 5.6%
- 3.1%
- 16.2%
- 10.0%
- 6.8%
- 12.1%
Growth
- +10.4%
- –
- −36.8%
- –
- +3.8%
Financial health
- 1.3×
- 0.45
- 29.5%
- 87.4×
- 21.28
- 20.95
- 0.18
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 49%of 957
Top 28%of 889
Bottom 22%of 601
Bottom 49%of 884
Bottom 44%of 986
What analysts expect
- Average price target
- $267.75
- Range
- $252.00 – $289.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | 1.63 | 1.84 | −11.4% |
| Feb 26, 2026 | 2.02 | 1.46 | +38.4% |
| Nov 6, 2025 | 3.09 | 1.97 | +56.9% |
| Aug 7, 2025 | 1.60 | 1.54 | +3.9% |
| May 8, 2025 | 1.33 | 1.30 | +2.3% |
| Feb 27, 2025 | -1.64 | 1.37 | −219.7% |
| Nov 7, 2024 | -0.39 | 0.75 | −152.0% |
| Aug 6, 2024 | 1.40 | 1.10 | +27.3% |
News
Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregationSeeking Alpha · Sep 25, 2026The newest story we have is from Sep 25, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
33No pass
Philip Fisher
41No pass
Peter Lynch
75Pass
Joel Greenblatt
7No pass
Charlie Munger
36No pass
Terry Smith
34No pass
Questions about Ligand Pharmaceuticals
Is Ligand Pharmaceuticals a good stock to buy?
A strong, very profitable business, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ligand Pharmaceuticals AI analysis
What does Ligand Pharmaceuticals do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. It is in Biotechnology, based in Jupiter, FL, United States, with 47 employees.
Does Ligand Pharmaceuticals pay a dividend?
No. Ligand Pharmaceuticals does not pay a dividend at the moment; in 2025 it returned $15.0 million to shareholders by buying back its own shares.
Is Ligand Pharmaceuticals stock halal?
Yes. Ligand Pharmaceuticals passes our halal screen: its business is permitted and its debt is 7% of its market value, under the 30% limit. How we check
How has Ligand Pharmaceuticals stock done over the past year?
Up 53.8% over the past twelve months, to $316.27. It traded between $181.65 and $322.75 and is 2.0% below its high.
Who are Ligand Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Ligand Pharmaceuticals's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.